Home > Companies > Irvine Scientific

Irvine Scientific

irvinesci.com

Irvine Scientific, a member of JX Holdings Group, is a worldwide leader in the innovation and manufacture of cell culture media, reagents, and medical devices for researchers and clinicians. The company provides unrivalled service and quality to scientists working in cell therapy and regenerative medicine, assisted reproductive technology and cytogenetics, and industrial cell culture for the large-scale production of biotherapeutics and vaccines. Irvine Scientific adheres to both ISO and FDA regulations and operates dual cGMP manufacturing facilities in California, USA and Tokyo, Japan.

C-Suite On Deck

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Events

8th International Conference on Bio-Sensing Technology

Conference

Related News

Cell and Gene Therapy

SPECIFIC BIOLOGICS INC. ANNOUNCES THERAPEUTIC DEVELOPMENT AWARD FROM THE CYSTIC FIBROSIS FOUNDATION

Specific Biologics Inc. | December 08, 2021

Specific Biologics Inc. an early-stage biotechnology company developing novel gene editing technologies, announced that it will receive more than US$527,000 to support the preclinical development of its Dualase™ gene editing platform to target a set of cystic fibrosis -causing nonsense mutations where patients currently have fewer therapeutic options available. "Incredible advancements in the treatment of cystic fibrosis have been made since the id...

AVENUEB CREATES A PATH TO SUCCESS FOR BIOLOGY STUDENTS

UC Davis | April 14, 2020

The Genentech Foundation has donated $2.5 million to the University of California, Davis, College of Biological Sciences — the college’s largest single gift ever — to fund a program that will help biology students transferring from community college. Called AvenueB, the program will provide financial support and preparatory programs for students going to four-year university. According to the Campaign for College Opportunity, students transferring from community colleges to a U...

MedTech

PFIZER TO ACQUIRE TRILLIUM THERAPEUTICS INC.

Pfizer Inc | August 24, 2021

Pfizer Inc. and Trillium Therapeutics Inc. today announced that the companies have entered into a definitive agreement under which Pfizer will acquire Trillium, a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer. Under the terms of the agreement, Pfizer will acquire all outstanding shares of Trillium not already owned by Pfizer for an implied equity value of $2.26 billion, or $18.50 per share, in cash. This represents a 118% premium to the 60-day...

Industrial Impact

CYBIN ANNOUNCES ADDITIONAL ADELIA MILESTONE ACHIEVEMENT

Cybin Inc. | January 28, 2022

Cybin Inc. a biotechnology company focused on progressing Psychedelics to Therapeutics™, is pleased to announce that Adelia Therapeutics Inc. a wholly-controlled subsidiary of Cybin, has achieved the milestones identified as Y1, Q4 (iv), Y1, Q4 (v) and Y2, Q1 (vi) as contemplated by the terms of a contribution agreement dated December 4, 2020 among Cybin, Cybin Corp., Cybin US Holdings Inc. a wholly-controlled subsidiary of Cybin, and all of the previous shareholders of Adelia.
Read More

Cell and Gene Therapy